company background image
REG1

Revenio Group Oyj HLSE:REG1V Stock Report

Last Price

€36.78

Market Cap

€977.6m

7D

-9.2%

1Y

-32.9%

Updated

29 Sep, 2022

Data

Company Financials +
REG1V fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance6/6
Financial Health5/6
Dividends0/6

REG1V Stock Overview

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally.

Revenio Group Oyj Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Revenio Group Oyj
Historical stock prices
Current Share Price€36.78
52 Week High€60.05
52 Week Low€36.02
Beta1.48
1 Month Change-18.19%
3 Month Change-15.68%
1 Year Change-32.94%
3 Year Change78.98%
5 Year Change204.72%
Change since IPO1,835.83%

Recent News & Updates

Sep 17
Is Revenio Group Oyj (HEL:REG1V) Potentially Undervalued?

Is Revenio Group Oyj (HEL:REG1V) Potentially Undervalued?

While Revenio Group Oyj ( HEL:REG1V ) might not be the most widely known stock at the moment, it saw significant share...

Aug 20
A Look At The Fair Value Of Revenio Group Oyj (HEL:REG1V)

A Look At The Fair Value Of Revenio Group Oyj (HEL:REG1V)

Today we will run through one way of estimating the intrinsic value of Revenio Group Oyj ( HEL:REG1V ) by taking the...

Jun 14
Does Revenio Group Oyj (HEL:REG1V) Have A Healthy Balance Sheet?

Does Revenio Group Oyj (HEL:REG1V) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Jun 01
Why Revenio Group Oyj (HEL:REG1V) Could Be Worth Watching

Why Revenio Group Oyj (HEL:REG1V) Could Be Worth Watching

Revenio Group Oyj ( HEL:REG1V ), might not be a large cap stock, but it led the HLSE gainers with a relatively large...

Shareholder Returns

REG1VFI Medical EquipmentFI Market
7D-9.2%-8.1%-2.5%
1Y-32.9%-46.8%-20.1%

Return vs Industry: REG1V exceeded the Finnish Medical Equipment industry which returned -45.1% over the past year.

Return vs Market: REG1V underperformed the Finnish Market which returned -18.3% over the past year.

Price Volatility

Is REG1V's price volatile compared to industry and market?
REG1V volatility
REG1V Average Weekly Movement6.1%
Medical Equipment Industry Average Movement9.7%
Market Average Movement5.1%
10% most volatile stocks in FI Market8.0%
10% least volatile stocks in FI Market3.4%

Stable Share Price: REG1V is not significantly more volatile than the rest of Finnish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: REG1V's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001194Jouni Toijalahttps://www.reveniogroup.fi

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities.

Revenio Group Oyj Fundamentals Summary

How do Revenio Group Oyj's earnings and revenue compare to its market cap?
REG1V fundamental statistics
Market Cap€977.57m
Earnings (TTM)€20.22m
Revenue (TTM)€88.36m

48.3x

P/E Ratio

11.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
REG1V income statement (TTM)
Revenue€88.36m
Cost of Revenue€24.92m
Gross Profit€63.43m
Other Expenses€43.21m
Earnings€20.22m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 27, 2022

Earnings per share (EPS)0.76
Gross Margin71.79%
Net Profit Margin22.89%
Debt/Equity Ratio27.0%

How did REG1V perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

45%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is REG1V undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REG1V?

Other financial metrics that can be useful for relative valuation.

REG1V key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.1x
Enterprise Value/EBITDA33.2x
PEG Ratio2.5x

Price to Earnings Ratio vs Peers

How does REG1V's PE Ratio compare to its peers?

REG1V PE Ratio vs Peers
The above table shows the PE ratio for REG1V vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average21x
NXTMH Nexstim
7.6x-31.4%€25.3m
BIOBV Biohit Oyj
44.7xn/a€22.3m
TTALO Terveystalo Oyj
13.7x13.8%€1.0b
OKDBV Oriola Oyj
18x2.4%€328.8m
REG1V Revenio Group Oyj
48.3x19.4%€977.6m

Price-To-Earnings vs Peers: REG1V is expensive based on its Price-To-Earnings Ratio (48.3x) compared to the peer average (21x).


Price to Earnings Ratio vs Industry

How does REG1V's PE Ratio compare vs other companies in the European Medical Equipment Industry?

Price-To-Earnings vs Industry: REG1V is expensive based on its Price-To-Earnings Ratio (48.3x) compared to the European Medical Equipment industry average (25.1x)


Price to Earnings Ratio vs Fair Ratio

What is REG1V's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REG1V PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio48.3x
Fair PE Ratio31.5x

Price-To-Earnings vs Fair Ratio: REG1V is expensive based on its Price-To-Earnings Ratio (48.3x) compared to the estimated Fair Price-To-Earnings Ratio (31.5x).


Share Price vs Fair Value

What is the Fair Price of REG1V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REG1V (€36.78) is trading below our estimate of fair value (€45.31)

Significantly Below Fair Value: REG1V is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Revenio Group Oyj forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


19.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: REG1V's forecast earnings growth (19.4% per year) is above the savings rate (0.2%).

Earnings vs Market: REG1V's earnings (19.4% per year) are forecast to grow faster than the Finnish market (7.2% per year).

High Growth Earnings: REG1V's earnings are forecast to grow, but not significantly.

Revenue vs Market: REG1V's revenue (17.5% per year) is forecast to grow faster than the Finnish market (2% per year).

High Growth Revenue: REG1V's revenue (17.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: REG1V's Return on Equity is forecast to be high in 3 years time (28%)


Discover growth companies

Past Performance

How has Revenio Group Oyj performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


24.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: REG1V has high quality earnings.

Growing Profit Margin: REG1V's current net profit margins (22.9%) are higher than last year (22.5%).


Past Earnings Growth Analysis

Earnings Trend: REG1V's earnings have grown significantly by 24.4% per year over the past 5 years.

Accelerating Growth: REG1V's earnings growth over the past year (25.9%) exceeds its 5-year average (24.4% per year).

Earnings vs Industry: REG1V earnings growth over the past year (25.9%) exceeded the Medical Equipment industry -0.3%.


Return on Equity

High ROE: REG1V's Return on Equity (25.5%) is considered high.


Discover strong past performing companies

Financial Health

How is Revenio Group Oyj's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: REG1V's short term assets (€36.7M) exceed its short term liabilities (€18.9M).

Long Term Liabilities: REG1V's short term assets (€36.7M) exceed its long term liabilities (€21.8M).


Debt to Equity History and Analysis

Debt Level: REG1V's net debt to equity ratio (5.5%) is considered satisfactory.

Reducing Debt: REG1V's debt to equity ratio has increased from 6.5% to 27% over the past 5 years.

Debt Coverage: REG1V's debt is well covered by operating cash flow (99.1%).

Interest Coverage: REG1V's interest payments on its debt are well covered by EBIT (1228.7x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Revenio Group Oyj current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.92%

Current Dividend Yield

Dividend Yield vs Market

Revenio Group Oyj Dividend Yield vs Market
How does Revenio Group Oyj dividend yield compare to the market?
SegmentDividend Yield
Company (Revenio Group Oyj)0.9%
Market Bottom 25% (FI)2.9%
Market Top 25% (FI)5.5%
Industry Average (Medical Equipment)1.9%
Analyst forecast in 3 Years (Revenio Group Oyj)1.3%

Notable Dividend: REG1V's dividend (0.92%) isn’t notable compared to the bottom 25% of dividend payers in the Finnish market (2.82%).

High Dividend: REG1V's dividend (0.92%) is low compared to the top 25% of dividend payers in the Finnish market (5.44%).


Stability and Growth of Payments

Stable Dividend: REG1V is not paying a notable dividend for the Finnish market, therefore no need to check if payments are stable.

Growing Dividend: REG1V is not paying a notable dividend for the Finnish market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: REG1V is not paying a notable dividend for the Finnish market.


Cash Payout to Shareholders

Cash Flow Coverage: REG1V is not paying a notable dividend for the Finnish market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Jouni Toijala (54 yo)

2.33yrs

Tenure

€213,036

Compensation

Mr. Jouni Toijala, B.Sc., MBA serves as Chief Executive Officer of Revenio Group Oyj. He served as Chief Executive Officer of Innokas Medical Oy. He served as Managing Director of EMEA at Symbio, Inc. Mr....


CEO Compensation Analysis

Jouni Toijala's Compensation vs Revenio Group Oyj Earnings
How has Jouni Toijala's remuneration changed compared to Revenio Group Oyj's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

€20m

Mar 31 2022n/an/a

€18m

Dec 31 2021n/an/a

€17m

Sep 30 2021n/an/a

€18m

Jun 30 2021n/an/a

€16m

Mar 31 2021n/an/a

€15m

Dec 31 2020€213k€132k

€13m

Compensation vs Market: Insufficient data to establish whether Jouni's total compensation is reasonable compared to companies of similar size in the Finnish market.

Compensation vs Earnings: Insufficient data to compare Jouni's compensation with company performance.


Leadership Team

Experienced Management: REG1V's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: REG1V's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of REG1V?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders54,8470.2%
Institutions13,125,57149.4%
General Public13,398,37750.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 47.05% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.16%
William Demant Invest A/S
4,028,205€148.2m14.77%2.54%
4.87%
SEB Investment Management AB
1,295,568€47.7m0%0.12%
4.35%
Columbia Management Investment Advisers, LLC
1,156,515€42.5m0%0.01%
2.98%
Capital Research and Management Company
792,790€29.2m0%no data
2.64%
The Vanguard Group, Inc.
701,508€25.8m0%no data
2.3%
Groupama Asset Management
612,274€22.5m0%0.43%
2.04%
Norges Bank Investment Management
543,041€20.0m0%no data
1.96%
Ilmarinen Pension Insurance Co. Ltd, Asset Management Arm
520,000€19.1m0%0.2%
1.54%
BlackRock, Inc.
410,444€15.1m0%no data
1.4%
Nordea Investment Management AB
371,113€13.6m0%0.01%
1.38%
Teknik Innovation Norden Fonder AB
367,869€13.5m0%3.68%
1.09%
Dimensional Fund Advisors LP
288,988€10.6m0.49%no data
0.81%
Artisan Partners Limited Partnership
216,572€8.0m18.54%0.01%
0.76%
Lannebo Fonder AB
201,744€7.4m0%0.16%
0.63%
Joh. Berenberg, Gossler & Co. KG, Asset Management Arm
167,197€6.1m-16.79%0.2%
0.49%
SP-Rahastoyhtiö Oy
130,492€4.8m0%0.33%
0.46%
Rainier Investment Management, LLC
122,141€4.5m6.47%0.36%
0.4%
Allianz Asset Management AG
106,125€3.9m0%no data
0.39%
Lonvia Capital
102,444€3.8m37.8%1.71%
0.26%
Natixis Investment Managers International
70,000€2.6m0%0.01%
0.24%
Wellington Management Group LLP
64,563€2.4m0%no data
0.23%
Bessemer Investment Management LLC
60,566€2.2m-12.75%no data
0.23%
Fondbolaget Fondita AB
60,000€2.2m0%0.38%
0.23%
Credit Suisse Asset Management (Switzerland)
59,905€2.2m0%no data
0.21%
Banque Carnegie Luxembourg S.A., Asset Management Arm
55,000€2.0m-5.17%1.45%

Company Information

Revenio Group Oyj's employee growth, exchange listings and data sources


Key Information

  • Name: Revenio Group Oyj
  • Ticker: REG1V
  • Exchange: HLSE
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €977.568m
  • Shares outstanding: 26.58m
  • Website: https://www.reveniogroup.fi

Number of Employees


Location

  • Revenio Group Oyj
  • Äyritie 22
  • Vantaa
  • Uusimaa
  • 1510
  • Finland


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REG1VHLSE (OMX Nordic Exchange Helsinki)YesOrdinary SharesFIEUROct 2001
REVX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2001
0KFHLSE (London Stock Exchange)YesOrdinary SharesGBEUROct 2001
REG1VHBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEUROct 2001
R0VMUN (Boerse Muenchen)YesOrdinary SharesDEEUROct 2001
R0VDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2001

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/29 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.